Tight Phosphate Control in ESKD Patients Is Warranted: Commentary.
作者信息
Gutiérrez Orlando M
机构信息
Departments of Medicine and Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama.
出版信息
Kidney360. 2024 Dec 13;6(6):898-899. doi: 10.34067/KID.0000000661.
Abstract
摘要
相似文献
1
Tight Phosphate Control in ESKD Patients Is Warranted: Commentary.对终末期肾病患者进行严格的磷酸盐控制是必要的：评论。
Kidney360. 2024 Dec 13;6(6):898-899. doi: 10.34067/KID.0000000661.
2
Tight Phosphate Control in ESKD Patients Is Warranted: PRO.ESKD患者应严格控制磷酸盐：正方观点。
Kidney360. 2024 Dec 13;6(6):892-894. doi: 10.34067/KID.0000000679.
3
Effectiveness of educational or behavioral interventions on adherence to phosphate control in adults receiving hemodialysis: a systematic review.教育或行为干预对接受血液透析的成年人控制磷水平依从性的有效性：一项系统评价。
JBI Database System Rev Implement Rep. 2017 Apr;15(4):971-1010. doi: 10.11124/JBISRIR-2017-003360.
4
Tight Phosphate Control in ESKD Patients Is Warranted: CON.ESKD患者应严格控制磷酸盐：赞成。
Kidney360. 2024 Dec 13;6(6):895-897. doi: 10.34067/KID.0000000000000401.
5
The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.司维拉姆和镧与含钙及铁基结合剂治疗慢性肾脏病患者高磷血症的疗效和安全性：一项系统评价和荟萃分析。
Nephrol Dial Transplant. 2017 Jan 1;32(1):111-125. doi: 10.1093/ndt/gfw312.
6
Phosphate binders in chronic kidney disease: a systematic review of recent data.慢性肾脏病中的磷结合剂：近期数据的系统评价
J Nephrol. 2016 Jun;29(3):329-340. doi: 10.1007/s40620-016-0266-9. Epub 2016 Jan 22.
7
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.1α(OH)D3 一α-羟基胆钙化醇——一种活性维生素 D 类似物。关于慢性透析的尿毒症患者继发性甲状旁腺功能亢进症预防和治疗的临床研究。
Dan Med Bull. 2008 Nov;55(4):186-210.
8
Hyperphosphatemia and phosphate binders.高磷血症与磷结合剂
Am J Health Syst Pharm. 2005 Nov 15;62(22):2355-61. doi: 10.2146/ajhp050198.
9
[Management of hyperphosphatemia in dialysis patients: the role of phosphate binders].[透析患者高磷血症的管理：磷结合剂的作用]
G Ital Nefrol. 2010 Nov-Dec;27 Suppl 52:S47-54.
10
Contemporary management of phosphorus retention in chronic kidney disease: a review.慢性肾脏病磷潴留的当代管理：综述
Clin Exp Nephrol. 2015 Dec;19(6):985-99. doi: 10.1007/s10157-015-1126-y. Epub 2015 Jun 2.
本文引用的文献
1
Tight Phosphate Control in ESKD Patients Is Warranted: PRO.ESKD患者应严格控制磷酸盐：正方观点。
Kidney360. 2024 Dec 13;6(6):892-894. doi: 10.34067/KID.0000000679.
2
Tight Phosphate Control in ESKD Patients Is Warranted: CON.ESKD患者应严格控制磷酸盐：赞成。
Kidney360. 2024 Dec 13;6(6):895-897. doi: 10.34067/KID.0000000000000401.
3
In Search of the Optimal Target for Phosphate Control: Episode 1.探寻磷酸盐控制的最佳靶点：第一集
J Am Soc Nephrol. 2021 Mar;32(3):526-528. doi: 10.1681/ASN.2021010027. Epub 2021 Feb 5.
4
The connection between dietary phosphorus, cardiovascular disease, and mortality: where we stand and what we need to know.饮食磷与心血管疾病和死亡率之间的关系：我们的立场和需要了解的情况。
Adv Nutr. 2013 Nov 6;4(6):723-9. doi: 10.3945/an.113.004812. eCollection 2013 Nov.
5
Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients.维持性透析患者的药丸负担、依从性、高磷血症及生活质量
Clin J Am Soc Nephrol. 2009 Jun;4(6):1089-96. doi: 10.2215/CJN.00290109. Epub 2009 May 7.
6
Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management.透析患者高磷血症和甲状旁腺功能亢进相关风险的重新评估：管理变更建议
Am J Kidney Dis. 2000 Jun;35(6):1226-37. doi: 10.1016/s0272-6386(00)70064-3.
Zotero 插件